A Phase Ib Study of Selinexor in Combination with Pembrolizumab in Patients with Metastatic Melanoma.
Saved in:
| Title: | A Phase Ib Study of Selinexor in Combination with Pembrolizumab in Patients with Metastatic Melanoma. |
|---|---|
| Authors: | Gouda MA; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Stephen B; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Tian Y; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Alshawa A; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Onwugaje DOC; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Albittar A; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Department of Hematopoietic Biology and Malignancy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Yang Y; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Zarifa A; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Yilmaz B; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Gurses S; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Sprenger A; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Derbala MH; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Brink A; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., How JA; Department of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Moyers J; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; The Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate, Los Angeles, CA, USA., Piha-Paul SA; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Hong DS; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Meric-Bernstam F; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Patel SP; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Oliva IG; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. |
| Source: | Journal of immunotherapy and precision oncology [J Immunother Precis Oncol] 2024 Nov 01; Vol. 7 (4), pp. 247-254. Date of Electronic Publication: 2024 Nov 01 (Print Publication: 2024). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Innovative Healthcare Institute Country of Publication: United States NLM ID: 101768397 Publication Model: eCollection Cited Medium: Internet ISSN: 2590-017X (Electronic) Linking ISSN: 2590017X NLM ISO Abbreviation: J Immunother Precis Oncol Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Links: – Type: pdflink Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 39524469 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: A Phase Ib Study of Selinexor in Combination with Pembrolizumab in Patients with Metastatic Melanoma. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Gouda+MA%22">Gouda MA</searchLink>; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Stephen+B%22">Stephen B</searchLink>; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Tian+Y%22">Tian Y</searchLink>; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Alshawa+A%22">Alshawa A</searchLink>; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Onwugaje+DOC%22">Onwugaje DOC</searchLink>; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Albittar+A%22">Albittar A</searchLink>; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Department of Hematopoietic Biology and Malignancy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Yang+Y%22">Yang Y</searchLink>; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Zarifa+A%22">Zarifa A</searchLink>; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Yilmaz+B%22">Yilmaz B</searchLink>; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Gurses+S%22">Gurses S</searchLink>; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Sprenger+A%22">Sprenger A</searchLink>; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Derbala+MH%22">Derbala MH</searchLink>; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Brink+A%22">Brink A</searchLink>; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22How+JA%22">How JA</searchLink>; Department of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Moyers+J%22">Moyers J</searchLink>; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; The Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate, Los Angeles, CA, USA.<br /><searchLink fieldCode="AU" term="%22Piha-Paul+SA%22">Piha-Paul SA</searchLink>; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Hong+DS%22">Hong DS</searchLink>; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Meric-Bernstam+F%22">Meric-Bernstam F</searchLink>; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Patel+SP%22">Patel SP</searchLink>; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Oliva+IG%22">Oliva IG</searchLink>; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22101768397%22">Journal of immunotherapy and precision oncology</searchLink> [J Immunother Precis Oncol] 2024 Nov 01; Vol. 7 (4), pp. 247-254. <i>Date of Electronic Publication: </i>2024 Nov 01 (<i>Print Publication: </i>2024). – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Innovative+Healthcare+Institute%22">Innovative Healthcare Institute </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101768397 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Internet <i>ISSN: </i>2590-017X (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%222590017X%22">2590017X </searchLink><i>NLM ISO Abbreviation: </i>J Immunother Precis Oncol <i>Subsets: </i>PubMed not MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=39524469 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.36401/JIPO-24-3 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 247 Titles: – TitleFull: A Phase Ib Study of Selinexor in Combination with Pembrolizumab in Patients with Metastatic Melanoma. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Gouda MA – PersonEntity: Name: NameFull: Stephen B – PersonEntity: Name: NameFull: Tian Y – PersonEntity: Name: NameFull: Alshawa A – PersonEntity: Name: NameFull: Onwugaje DOC – PersonEntity: Name: NameFull: Albittar A – PersonEntity: Name: NameFull: Yang Y – PersonEntity: Name: NameFull: Zarifa A – PersonEntity: Name: NameFull: Yilmaz B – PersonEntity: Name: NameFull: Gurses S – PersonEntity: Name: NameFull: Sprenger A – PersonEntity: Name: NameFull: Derbala MH – PersonEntity: Name: NameFull: Brink A – PersonEntity: Name: NameFull: How JA – PersonEntity: Name: NameFull: Moyers J – PersonEntity: Name: NameFull: Piha-Paul SA – PersonEntity: Name: NameFull: Hong DS – PersonEntity: Name: NameFull: Meric-Bernstam F – PersonEntity: Name: NameFull: Patel SP – PersonEntity: Name: NameFull: Oliva IG IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 11 Text: 2024 Nov 01 Type: published Y: 2024 Identifiers: – Type: issn-electronic Value: 2590-017X Numbering: – Type: volume Value: 7 – Type: issue Value: 4 Titles: – TitleFull: Journal of immunotherapy and precision oncology Type: main |
| ResultId | 1 |
